skip to main content
UK Health Security Agency

NZOV9

NZOV9

Catalogue No.

17020215

Cell Line Name

NZOV9

Cell Line Description

The NZOV9 is a semi adherent cell line derived from a poorly differentiated serous adenocarcinoma of the ovary of a 47 year old female patient.Aneuploid 2.11x diploidMutant PI3K enzyme Y1021CWild-type p53 proteinThis cell line is distributed by ECACC on behalf of CellBank Australia, Children's Medical Research Institute, Westmead, NSW 2145, Australia. All stock supplied is manufactured and Quality Control released at source by CellBank Australia. CellBank Australia reference number: CBA-1394.

Characteristics

Tissue of Origin

Ovary

Morphology

Adherent cells have an epithelial morphology, the cell line grows in clusters of small cells

Disease

Adenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Remove protective cryoflex layer around the ampoule prior to thawing. Thaw the ampoule by gently agitating in a 37°C waterbath; thawing should be rapid (around 2 minutes). A centrifugation step to remove the cryoprotectant after thawing is necessary for this cell line. Medium Renewal: 3 times per week. Subcultivation ratio: 1:10, Seeding density 1.0 - 2.0 x10⁴ cells/cm². Split subconfluent cultures (70-80%). Collect the cells in suspension and harvest the adherent cells using 0.05% Trypsin/EDTA at 37°C for 5 minutes. Combine both populations for subculture. Culture conditions: Incubate the culture at 37°C with 5% CO₂. Cryoprotectant Medium: 10% DMSO + 90% FCS

Culture Medium

This cell line was established by the depositor in: Alpha modified Minimum Essential Medium (MEM) supplemented with 5% Foetal Bovine Serum (FBS), 5 µg/ml Insulin, 5 µg/ml Transferrin, 5 ng/ml Sodium Selenite (ITS), 5 ng/ml EGF and 10nM Estradiol in an atmosphere of 5% O₂, 5% CO₂ and 90% N₂.At CellBank Australia it has been cultured in: MEM alpha + 5% FBS + ITS (5 µg/ml Insulin, 5 µg/ml Transferrin, 5 ng/ml Sodium Selenite) in 5% CO₂.

Growth Mode

Adherent and floating viable cells

Additional Info

Depositor

Professor Bruce Baguley - The University of Auckland

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Baguley BC, Marshall ES, Whittaker JR, Dotchin MC, Nixon J, McCrystal MR, Finlay GJ, Matthews JHL, Holdaway KM, van Zijl P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur J Cancer 1995; 31A: 230-237 PMID: 7718330

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: NZOV9 (ECACC 17020215).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.